Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | LsmAD domain-containing protein | 0.0028 | 1 | 0.5 |
Echinococcus multilocularis | lamin | 0.0026 | 0.8927 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0028 | 1 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0028 | 1 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0028 | 1 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0028 | 1 | 0.5 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0028 | 1 | 0.5 |
Schistosoma mansoni | intermediate filament proteins | 0.0026 | 0.8927 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0028 | 1 | 1 |
Brugia malayi | hypothetical protein | 0.0018 | 0.2806 | 0.2806 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0028 | 1 | 0.5 |
Brugia malayi | intermediate filament protein | 0.0026 | 0.8927 | 0.8927 |
Schistosoma mansoni | lamin | 0.0026 | 0.8927 | 0.5 |
Echinococcus granulosus | intermediate filament protein | 0.0026 | 0.8927 | 0.5 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0026 | 0.8927 | 0.8927 |
Echinococcus granulosus | lamin dm0 | 0.0026 | 0.8927 | 0.5 |
Onchocerca volvulus | 0.0026 | 0.8927 | 0.5 | |
Loa Loa (eye worm) | hypothetical protein | 0.0026 | 0.8575 | 0.8575 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0028 | 1 | 0.5 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0026 | 0.8927 | 0.8927 |
Schistosoma mansoni | lamin | 0.0026 | 0.8927 | 0.5 |
Echinococcus multilocularis | musashi | 0.0026 | 0.8927 | 0.5 |
Loa Loa (eye worm) | intermediate filament protein | 0.0026 | 0.8927 | 0.8927 |
Onchocerca volvulus | 0.0026 | 0.8927 | 0.5 | |
Echinococcus granulosus | lamin | 0.0026 | 0.8927 | 0.5 |
Echinococcus multilocularis | lamin dm0 | 0.0026 | 0.8927 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0026 | 0.8927 | 0.8927 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.